The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease
Open accessAbstract
Summary Neuroactive metabolites of the kynurenine pathway (KP) of tryptophan degradation have been implicated in the pathophysiology of neurodegenerative disorders, including Huntington’s disease (HD) [1]. A central hallmark of HD is neurodegeneration caused by a polyglutamine expansion in the huntingtin (htt) protein [2]. Here we exploit a transgenic Drosophila melanogaster model of HD to interrogate the therapeutic potential of KP manipulation. We observe that genetic and pharmacological inhibition of kynurenine 3-monooxygenase (KMO) increases levels of the neuroprotective metabolite kynurenic acid (KYNA) relative to the neurotoxic metabolite 3-hydroxykynurenine (3-HK) and ameliorates neurodegeneration. We also find that genetic inhibition of tryptophan 2,3-dioxygenase (TDO), the first and rate-limiting step in the pathway, leads to a similar neuroprotective shift toward KYNA synthesis. Importantly, we demonstrate that the feeding of KYNA and 3-HK to HD model flies directly modulates neurodegeneration, underscoring the causative nature of these metabolites. This study provides the first genetic evidence that inhibition of KMO and TDO activity protects against neurodegenerative disease in an animal model, indicating that strategies targeted at two key points within the KP may have therapeutic relevance in HD, and possibly other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Self-citationHistone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H.-Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 515
Self-citationFoster, A. C., Vezzani, A., French, E. D., & Schwarcz, R. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90050-8 · Cited by 434
Self-citationGiorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., & Muchowski, P. J. (2005) · Nature Genetics · doi:10.1038/ng1542 · Cited by 328
Self-citationThe kynurenine pathway of tryptophan degradation as a drug target
Schwarcz, R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.006 · Cited by 265
Self-citationPresynaptic kynurenate‐sensitive receptors inhibit glutamate release
Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M., & Moroni, F. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01592.x · Cited by 254
Röver, S., Cesura, A. M., Huguenin, P., Kettler, R., & Szente, A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970467t · Cited by 211
Roberts, J. E. (2001) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(01)00196-8 · Cited by 178
Romero, E., Cha, G.-H., Verstreken, P., Ly, C. V., Hughes, R. E., Bellen, H. J., & Botas, J. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.025 · Cited by 170
On the relationship between the two branches of the kynurenine pathway in the rat brainin vivo
Amori, L., Guidetti, P., Pellicciari, R., Kajii, Y., & Schwarcz, R. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05893.x · Cited by 154
Self-citationZádori, D., Nyíri, G., Szőnyi, A., Szatmári, I., Fülöp, F., Toldi, J., Freund, T. F., Vécsei, L., & Klivènyi, P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0573-6 · Cited by 112
VanDongen, A. M. J. (2008) · CRC Press eBooks · doi:10.1201/9781420044157 · Cited by 105
Giorgini, F., Möller, T., Kwan, W., Zwilling, D., Wacker, J. L., Hong, S. Y., Tsai, L. L., Cheah, C. S., Schwarcz, R. M., Guidetti, P., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708192200 · Cited by 98
Self-citationEarly kynurenergic impairment in Huntington's Disease and in a transgenic animal model
Guidetti, P., Reddy, P. H., Tagle, D. A., & Schwarcz, R. M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00956-3 · Cited by 97
Self-citationRafice, S. A., Chauhan, N., Efimov, I., Basran, J., & Raven, E. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370408 · Cited by 83
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Thevandavakkam, M., Schwarcz, R., Muchowski, P., & Giorgini, F. (2010) · CNS and Neurological Disorders - Drug Targets · doi:10.2174/187152710793237430 · Cited by 80
Self-citationOxenkrug, G. F. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0341-7 · Cited by 77
Savvateeva, E. V., Popov, A. V., Камышев, Н. Г., Bragina, J. V., Heisenberg, M., Senitz, D., Kornhuber, J., & Riederer, P. F. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070080 · Cited by 74
Tissue specific effects of ommochrome pathway mutations inDrosophila melanogaster
Tearle, R. G. (1991) · Genetics Research · doi:10.1017/s0016672300029402 · Cited by 67
Lansdell, S. J., & Millar, N. S. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02499.x · Cited by 66
Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites
Hiraku, Y., Inoue, S., Oikawa, S., Yamamoto, K., Saeko, T., Nishino, K., & Kawanishi, S. (1995) · Carcinogenesis · doi:10.1093/carcin/16.2.349 · Cited by 63
Radical Scavenging Properties of Tryptophan Metabolites
Goda, K., Hamane, Y., KISHIMOTO, R., & Ogishi, Y. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4709-9_50 · Cited by 61
Alkondon, M., Pereira, E. F. R., Eisenberg, H. M., Kajii, Y., Schwarcz, R. M., & Albuquerque, E. X. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.177386 · Cited by 36
Self-citationVécsei, L., & Beal, M. F. (1990) · Brain Research Bulletin · doi:10.1016/0361-9230(90)90123-h · Cited by 33
Yagi, S., & Ogawa, H. (1996) · ZOOLOGICAL SCIENCE · doi:10.2108/zsj.13.97 · Cited by 17
Xia, S., & Chiang, A. (2009) · Europe PMC (PubMed Central) · Cited by 13
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Self-citationNAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
Metadata
- Authors
- Campesan, S., Green, E. W., Breda, C., Sathyasaikumar, K. V., Muchowski, P. J., Schwarcz, R., Kyriacou, C. P., & Giorgini, F.
- Venue
- Current Biology
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 21
- Issue
- 11
- Pages
- 961-966
- ISSN
- 0960-9822 (ISSN-L)
- OpenAlex
- W1974769584
- Cited by
- 258
- References
- 30
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.